Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LinearDNA COVID-19 vaccine (feline)
- Development stage
- Unknown
- Lead developer
- EvviVax
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The LinearDNA COVID-19 vaccine (feline) is a PCR-produced linear DNA vaccine developed by EvviVax in collaboration with Applied DNA Sciences and Takis Biotech. It is designed to prevent SARS-CoV-2 infection in domestic cats by encoding the SARS-CoV-2 spike protein. The vaccine aims to induce both neutralizing antibodies and cellular (T-cell) immunity. It is administered intramuscularly using gene electrotransfer and is provided in a lyophilized (freeze-dried) form. The primary goal of the vaccine is to prevent felines from acting as a viral reservoir for human transmission. Phase 1 clinical trials have demonstrated safety, tolerability, and the ability to generate neutralizing antibodies against multiple SARS-CoV-2 variants, including B.1.1.7, P.1, and B.1.526.
- Other names
- LinearDNA COVID-19 vaccineEvviVax feline COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on LinearDNA COVID-19 vaccine (feline).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LinearDNA COVID-19 vaccine (feline).